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Canine visceral leishmaniasis is an increasingly important public health problem. Dogs
infected by Leishmania infantum are the main domestic reservoir of the parasite and play
a key role in its transmission to humans. Recent findings have helped in the development
of novel diagnostic methods, and of control measures such as vaccines, some of which
are already commercially available. However, quantitative procedures should be followed
to confirm whether these vaccines elicit a cell-mediated immune response. The present
work describes the need for this evaluation, and the techniques available for confirming
this type of immune response.
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ZOONOTIC VISCERAL LEISHMANIASIS: A GROWING PUBLIC
HEALTH CONCERN
Zoonotic visceral leishmaniasis (ZVL) is a vector-borne disease caused by the protozoan
parasite Leishmania infantum (syn. Leishmania chagasi). In the Old World the parasite is
transmitted by the bite of sand flies belonging to the genus Phlebotomus; in the New World the
members of the genus Lutzomyia takes on this role. ZVL occurs in Mediterranean Europe, in
North Africa and the Near East, Central Asia, China and Latin America, appearing in foci that
coincide precisely with the geographical distribution of the disease vectors. The incidence of human
visceral leishmaniasis (HVL) is estimated at 4,500–6,800 cases in the Americas, 1,200–2,000 in
Mediterranean countries, and 5,000–10,000 across the Middle East to Central Asia (1).
Dogs, the main reservoir of the parasite, are susceptible to canine visceral leishmaniasis (CVL)
(Box 1). The seroprevalence of Leishmania for the canine population ranges from 3 to 30%
depending on the area and ecological variables (2). It is higher in areas where transmission can
occur throughout the year; for example, in the south of Bahia, Brazil, it may be as high as 50.3%
(3). However, when PCR-based tools are used for screening, prevalence figure can be even 3 times
higher than that detected by serology (4). Indeed, follow-up studies of dogs living in areas where
active transmission occurs show virtually all of them to have been in contact with the parasite at
some point in their lives (5).
Wild animals such as wolves, jackals and foxes, hares and rabbits have also been described to
act as reservoirs of the parasite. However, the proximity of dogs to humans, the high prevalence
of infection among them, and the ease with which they transmit the parasite to sand flies, allow
for the domestic transmission of L. infantum to humans. Actually, several studies have reported a
correlation between the incidence of CVL and HVL (6).
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CVL is not, therefore, only an important veterinary problem;
it is also a major public health concern (7, 8). Infected dogs
are directly involved in the spread of ZVL to disease-free areas.
The appearance of cases of human leishmaniasis in previously
non-endemic areas is usually preceded by the appearance of
competent vectors and cases of CVL; such has been reported from
both northern Italy (9, 10) and northern Argentina (11). The
recent PAHO/WHO report on the human leishmaniasis situation
in the Americas indicates that while the total number of cases of
cutaneous leishmaniasis has remained stable over recent years,
the number of cases of HVL has increased by 26.4% in the region,
with increases in the fatality rate and number of deaths seen
since 2014 (12). The transmission of HVL is increasing in Brazil,
where the age-standardized disability-adjusted life years values
associated with the disease increased by 83.6% between 1990 and
2016, and the age-standardized incidence rate and the years of
life lost increased by 52.9 and 108% respectively over the same
period (13).
Preventing the expansion of ZVL and disease transmission to
humans requires surveillance of the vector, the implementation
of measures to reduce the prevalence and incidence of CVL, and
the development of procedures for assessing the impact of such
control measures in affected populations.
PREVENTION OF L. INFANTUM INFECTION
IN DOGS
The natural history of CVL is complex and depends on multiple
factors like nutritional and immunological state of the animal,
age, dog breed, or virulence of the parasite (14). The result is
a dynamic spectrum of naturally infected dogs ranging from
resistant, asymptomatic animals to those with severe disease
(15). The number of Leishmania-infected dogs is much higher
than the number that actually develops the disease; as a result,
the overall burden of infection in the canine population in
endemic areas is unknown (16). Some of these Leishmania-
infected asymptomatic animals may act as “carriers,” especially
if they harbor parasites in the skin; some 51% of the dogs from
endemic areas are PCR skin-positive (17). The existence of such
a significant source of parasites hinders the implementation of
effective control measures. Certainly, strategies involving drug
treatment for CVL have been shown unsuccessful; chemotherapy
does not clear parasites from dogs, and although the majority
improve clinically, relapses are frequent and the animals remain
infectious to sand flies (5). Eliminating seropositive dogs does not
help either; not only is it ethically unacceptable, it has been found
to have no influence on disease prevalence (18, 19).
In this complex scenario, the best option for the efficient
control of CVL is prevention, both of sand flies biting dogs (20),
and of dogs developing the disease (21). Several insecticides and
repellents are available in the form of collars, lotions and pipettes
that impregnate the animal’s skin and prevent sand fly bites.
Controlled trials of these products have returned good results
(22), but their effectiveness may decrease if dog owners fail to
maintain their use (23).
Box 1 | Main clinical characteristics and symptoms of canine
visceral leishmaniasis.
• Period of incubation varies between 2 and 8 months.
• The pathological spectrum of canine leishmaniasis ranges from an anergic
condition, with few or no clinical signs, to an hyperreactive form with severe
symptomatology.
• The distribution of the parasite is extensive, throughout the organism:
spleen, liver, lymph glands, bone marrow, kidney, and skin.
• A humoral response is produced, starting with polyclonal stimulation of B
cells and formation of immunocomplexes.
• EARLY SYMPTOMS steady loss of weight
asthenia
apathy.




• PATENT PERIOD lymphadenopathy
hepatomegaly
splenomegaly
skin lesions (ulcers) around the nose, ocular orbits
and ears
alopecia and peeling







• FINAL STAGE ulcers and bald patches are widespread
cachexia
opportunistic infections
renal or hepatic failure
Vaccines against CVL can provide dogs with specific, internal
protection against developing clinical disease. Strong, specific
and permanent immunity can be induced, preventing the
multiplication and dispersion of the parasite, ruling out the
development of CVL. The prophylactic vaccines currently
available represent a clear advance in the control of this disease.
Given their ease of use, and their cost/benefit ratio, prophylactic
vaccines are usually the most effective prevention and control
tools at our disposal (15).
Development of Vaccines for CVL: A
Challenging Task
Parasites are complex eukaryotic unicellular and multicellular
pathogens.Most have very complicated life cycles that include the
infection of intermediate invertebrate hosts; their morphological
and genetic complexity makes them challenging targets for
vaccines; and the parasites have evolved to resist the host
immune response by evading effectors or preventing their
production (24).
Early studies showed that parasites may trigger immediate-
type hypersensitivity or delayed-type hypersensitivity, both
mediated by CD4+ T helper (Th) cells (25). This reaction
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dichotomy was explained following the discovery that CD4+
T cells could be classified into multiple subsets depending
on their cytokine expression profile, i.e., Th1 cells expressing
interferon(IFN)-γ, interleukin(IL)-12 and/or tumor necrosis
factor (TNF)-α (inducing delayed -type hypersensitivity), and
Th2 cells expressing IL-4, IL-5, and IL-13 (promoting immediate-
type hypersensitivity) (26). In the case of the Leishmania
protozoan (an obligate intracellular parasite that infects
mammalian host macrophages), this reaction dichotomy was
demonstrated when BALB/c and C57BL6 mice experimentally
infected with Leishmania major promastigotes developed either
a Th2 or Th1 response associated respectively with either
exacerbation or healing of the infection (27) (Figure 1). To
prevent parasite multiplication and dissemination, an efficient
cell-mediated immune response is required, involving dendritic
cell-primed CD4+ (Th1 type) and CD8+ T lymphocytes that
produce IFN-γ, and/or IL-12, and/or TNF-α. These cytokines
activate infected macrophages to produce nitric oxide and
reactive oxygen species, which lead to the physical elimination of
the parasite (28). Leishmania has, however, evolved sophisticated
mechanisms that help it prevent these responses (29). It also
induces the expression of immunosuppressive IL-10, interferes
with the production of Leishmania-specific antibodies, and
stops the expansion of parasite-specific CD8-T cell clones, as
well as disables the antigen presenting capacity of macrophages
(30). Different high throughput techniques have shown that
Leishmania infection affects the expression of a multitude of
host genes (31), with the progress of the infection dependent
on the balance struck between the virulence of the parasite
and the host’s innate and adaptive immune responses (32). The
dichotomy in the reaction to Leishmania is seen in naturally
infected dogs from the same disease-endemic area developing
either severe CVL or remaining asymptomatic. The complexity
of host-parasite interactions hinders the development of effective
vaccines against CVL, certainly making it very difficult to identify
a single hallmark of protection against leishmaniasis. All the
factors involved in the response to infection by Leishmaniamust
therefore be studied in detail (15, 33).
For many years, dogs were thought the most susceptible host
in the transmission cycle, and that they had no possibility of
recovery (14). This idea developed because of the high percentage
of seropositive dogs that developed the disease, the large number
of cases of CVL in endemic areas compared to HVL, and the only
partial effectiveness of chemotherapy in sick animals. In contrast,
when active HVL is successfully treated, cell-mediated immunity
toward Leishmania spp. is developed (34, 35).
The observation that dogs naturally infected by L. infantum
could actually develop a protective response to the disease was
the proof of concept needed to show that the induction of
immune protection against canine leishmaniasis was feasible
FIGURE 1 | Dichotomy of the immune reaction to Leishmania, determined by the type of CD4 + T-cells and cytokines involved. In naturally infected dogs, resistance
or susceptibility to CVL depends on the immune response elicited. Protection is associated with Th1 cell-mediated immunity, with IL-2, TNF-α, and IFN- γ stimulating
the leishmanicidal activity of macrophages. Susceptibility is associated with a Th2 response and high antibody titres.
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TABLE 1 | Vaccine trials for canine visceral leishmaniasis.
Vaccine formulation Type of trial Cell immunity
test
Efficacy References
L. braziliensis sonicated promastigotes + BCG Experimental infection
2.3 × 106 promastigotes IV
CPA Partial - (41)
Purified fucose mannose lingand + QuilA saponin Phase III—Natural infection LST 80.0% (43)
Recombinant fusión protein Q Experimental infection
500,000 promastigotes IV
LST 90% (44)
Alum precipitated L. major autoclaved
promastigotes + BCG
Phase III—Natural infection LST 69.3% (42)
Recombinant proteins H1, HASPB1 + Montanide.
Polyprotein MML + MPL-SE
Experimental infection
1 × 108 promastigotes IV
CPA Partial (45)
Plasmid with CPA and CPB —recombinant protein
CPa, CPB + CpG ODN + Montanide.
Prime—boost vaccination
Experimental infection




DNA-LACK plasmid followed by rVaccinia virus












Attenuated line L. infantum H-line), established by
culturing promastigotes in vitro under gentamic in
pressure
Phase III—Natural infection None 93% (estimated) (49)





Alum precipitated autoclaved L. major mixed with
BCG and imiquimod
Phase III—Natural infection LST 40.4% (53)
L. tarentolae expressing the A2 and cistein
proteinases A and B proteins
Experimental infection




CPA, Cell Prilferation Assay; LST, Leishmanin Skin Test; CMLA, Canine Macrophage Leishmanicidal Assay.
(36). Several experimental infection trials later demonstrated that
it was possible to induce this protective response experimentally
(5). Nevertheless, obtaining an effective vaccine against CVL,
capable of inducing a safe, strong and prolonged Leishmania-
specific protective response in the dog, is a challenging task.
Eliciting this type of cell-mediated response by vaccination is
more difficult than obtaining a humoral response, especially
given the antigenic complexity of the pathogen and its possession
of evasion mechanisms (37).
Many strategies for inducing immunity against Leishmania
infection have been tested in murine models (with greater or
lesser success). These have been based on the use of killed
Leishmania parasites, attenuated parasites, different antigen
fractions, purified proteins, recombinant proteins, synthetic
peptides, non-protein antigens, bacterial and virus-expressed
parasite immunogens, and even “bare” parasite DNA (including
the DNA of plasmids or linear vectors) (38–40). Only a few have
been tried in dogs, however, because of the technical difficulties
involved in handling the experimental animals and the high costs
involved. Certainly, very few vaccine candidates for CVL have
been tested in double-blind randomized field trials.
Partial protection against CVL has been reported after
immunization with sonicated or autoclaved promastigotes (41,
42), with purified and recombinant Leishmania proteins (43–
46), with parasite DNA (47, 48), and with attenuated Leishmania
strains (49). A review summarizing the few efficacy studies
performed in dogs, involving different types of Leishmania
antigen (purified proteins, recombinant proteins or DNA),
adjuvants and post-vaccination Leishmania infantum challenge,
indicated different levels of protection to be obtained by
the different vaccine candidates (50). Later, the attenuated L.
donovani centrin-deleted strain [LdCen(-/-)] (when used as a
vaccine) was found to reduce the parasite burden of subsequently
infected dogs by up to 87.3% at 18 months post-challenge (51).
The immunogenicity of, and partial protection afforded by,
recombinant non-pathogenic Leishmania tarentolae expressing
the A2 and cystein proteinases A and B proteins has also been
reported (52). Alum-precipitated, autoclaved Leishmania major
mixed with Bacillus Calmette-Guérin (BCG) and imiquimod
was shown in a field trial to be of low efficacy in dogs
(53) (Table 1).
To date, three vaccines against CVL have been approved, one
in Brazil and two in Europe:
- Leish-Tec (Hertape Calier, Brazil), based on the recombinant
protein A2, with saponin as an adjuvant (54, 55),
- Canileish (Virbac, France) made with L. infantum
excreted/secreted antigens, with QA-21 as an adjuvant
(56), and
- Letifend (Laboratorios Leti, Spain), based on the fusion protein
Q, formulated without adjuvant (57).
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TABLE 2 | Comparison of CVL vaccines currently marketed.
VACCINE
(References)
LEISH-TEC (54) CANILEISH (58) LETIFEND (59)


















IgG2 expression YES YES YES
Th1 cells activation Not determined YES Not determined
IFN- γ expression after
stimulation
YES YES Not determined
Leishmanicidal activity Not determined YES Not determined
LST / DTH after
infection
Not determined YES YES
The level of protection and efficacy in the prevention of
disease reported for all three vaccines was similar (92–98 and 68–
72%, respectively) (54, 58, 59) (Table 2). However, Leish-Tec was
mainly assessed via the expression of induced antigen-specific
IgG2 antibodies (60), while Letifend was assessed via the cellular
immunity detected by the leishmanin skin test (57). In contrast,
Canileish was found to induce a specific humoral response as well
as specific cellular immunity, as confirmed by (i) the appearance
of Leishmania-specific Th1 cell clones able to produce IFN-
γ upon stimulation with leishmanial antigens, (ii) the induced
leishmanicidal activity of macrophages, and (iii) the increased
expression of iNOS and NO (which finally kills the parasite) (56).
The specific cell-mediated immune response against the parasite
was strong and remained effective against experimental challenge
at 1 year (46).
Assessing Immunity Against CVL
Usually, the assessment of the immunogenicity and efficacy
of CVL vaccines has consisted of the clinical, serological
and parasitological follow-up of vaccinated animals. However,
several procedures can be followed to quantify the level of
cell-mediated immunity (T cell memory) induced by natural
infection and experimental immunization (Table 3). Most are
based on the specific recognition of parasite antigens by
Leishmania-specific T cell clones. Tests should be periodically re-
performed, since in dogs the immune response to Leishmania can
change (15).
The Leishmanin Skin Test—LST
This involves the inoculation of phenolized promastigotes into
the epidermis and the measurement of the corresponding
intradermal reaction—a delayed-type hypersensitive (DTH)
response that can be examined under field conditions. This test
provides a physiological means of assessing the development of
Leishmania-specific cell-mediated immunity associated with the
state of “resistance” to the parasite. In humans, the LST is a
good detector of acquired protective immunity to Leishmania,
becoming positive after effective therapy for HVL (35, 61).
Further, the LST+ rate is inversely associated with the incidence
of HVL (e.g., in populations with an LST+ rate of >45%, few
cases of VL are seen).
LST is also a good method to assess anti-Leishmania
specific DTH cellular responses in dogs, particularly under
field conditions (62, 63). Most dogs that develop cell-mediated
immunity do so early in infection, although some dogs with
a positive LST result do develop clinical leishmaniasis (64, 65)
(note that asymptomatic dogs show stronger LST+ reactions
than do symptomatic ones). The LST+ reaction reflects a lack
of progression of the disease, making it one of the most useful
test for evaluating Leishmania-specific cell-mediated immunity
(66–69). An LST+ reactionmay indicate that the immune system
is controlling the infection, even in animals that have a positive
spleen culture (70). The use of LST in vaccine trials is limited
to phases IIb and III, when it becomes necessary to confirm a
Leishmania-specific cell-mediated response.
The in vitro Cell Proliferation Assay—CPA
This technique involves the in vitro stimulation of peripheral
blood mononuclear cells (PBMCs) with leishmanial soluble
antigen to confirm the presence of circulating Leishmania-
specific memory T cell clones. The degree of cell proliferation
(measured via the synthesis of DNA in the culture, or by cell
division), indicates the degree of specific cell-mediated immunity
against the parasite. Such testing has been used to assess the
antigenicity of Leishmania proteins in humans (71).
In dogs, the intensity of the CPA and LST responses are
correlated (52, 72), and a Leishmania-specific CPA+ response
is associated with recovery after treatment for CVL. Relapse
in treated animals is associated with the lack of, or the
disappearance of, a positive CPA result (73).
Unlike the LST, in vitro cell stimulation is a very useful
way of assaying the antigenicity of vaccine candidate proteins,
and for detecting specific cell responses after immunization. In
experimentally infected dogs, the CPA has successfully been used
to examine the antigenicity of different Leishmania proteins,
such as P-8 (74) HSP-70, KMP-11, PFR-2 (75) and PSA (76).
Stimulation with the specific proteins included in the vaccine
formulation also allows one to determine their capacity to induce
T cell memory clones (45, 56, 77–79), and to assess the duration
of the immunity produced (80).
CPA can be complemented with the analysis of the cytokines
(i.e., those involved in the Th1 response, but mainly IFN-γ,
the effector cytokine involved in the activation of macrophages
to kill the parasites) secreted into the supernatant, allowing
for a better characterization of the cellular responses activated.
CPA thus becomes an IFN-γ release assay (IGRA)—the type
of cell assay used to demonstrate immunity to intracellular
pathogens (51, 81–84).
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TABLE 3 | Methods for measuring cell-mediated immunity to leishmania infection or vaccination in dogs.




























- Antigenicity of Leishmania protein
- Immunogenicity of vaccine candidates
- Efficacy trials


























- Leishmania-specific functional CMI















SLA, Soluble leishmanial antigen;
PBMC, Peripheral blood mononuclear cells;
CMI, Cell-mediated immunity;
NO, Nitric oxide;
iNOS, Inducible nitric oxide synthase.
The ELISpot—IFN-γ Test
This is an IGRA-type test that combines the in vitro cell
stimulation of PBMCs with the in situ expression of IFN-
γ. This allows the direct quantification of the frequency
of T cell clones producing IFN-γ after challenge with the
leishmanial antigen—or vaccine stimulation—and therefore
determines the potency of the immunity induced. This assay
has proven useful for determining the immunological condition
of Leishmania-infected people who are LST- (85). IFN-γ
expression by Leishmania-specific T-cells is key in disease
resistance. Several studies report the predominant role of IFN-
γ in the activation of macrophages and the stimulation of
their leishmanicidal activity in mice [reviewed in (26, 86,
87)]. The same role has been confirmed in dogs; high IFN-
γ expression levels in peripheral blood lymphocytes from
asymptomatic animals following stimulation with leishmanial
antigen indicate a response to vaccination and are associated
with the absence of symptoms (74, 88–90). All the latter
studies emphasize the importance of T-cell-derived IFN-γ as
a hallmark of immunity, and highlight the suitability of this
approach when evaluating the efficacy of CVL vaccines. It
is important to note that while the IFN-γ levels related to
immunity to Leishmania are derived from T cells, the provenance
of the same cytokine present at high levels in serum and in
infected tissue is unsure, although it appears to be related
to an inflammatory response (91). The ELISpot—IFN-γ test
has been used to confirm the induction of cell-mediated
immunity in vaccinated dogs. PBMCs are stimulated with total




This is a complex assay performed in vitro to demonstrate that
the cell-mediated immune response elicited is fully functional
and can eliminate the parasite; it reveals the capacity of
Leishmania-specific T cell clones to induce the leishmanicidal
activity of infected macrophages when cultured together. This
activity is measured via the reduction in the number of
parasites present in cells after 72 h of co-culture. The test
can be combined with analyses of the expression of factors
such as IFN-γ, NO or iNOS which are directly involved
in this leishmanicidal activity (76). This strategy has been
used in laboratory studies to confirm immunogenicity after
vaccination in dogs, but it is very difficult to use under field
conditions (56, 80).
The Whole Blood Stimulation Assay—WBA
This recently developed IGRA-type test can be used to assess
asymptomatic Leishmania infection in humans; the results are
comparable to those provided by CPA (92). A peripheral
blood sample is stimulated with leishmanial antigens and the
cytokines/chemokines presents in the plasma determined after
24 h of incubation. IL-2, IFN-γ, IP-10, MIG, and MCP-1 are
all associated with a protective immune response (93–95).
In humans, this test has been used to confirm full recovery
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after treatment (94, 96). Our own epidemiological studies
involving dogs have confirmed that this is an easy-to-use, robust
field technique, and that it can be used to detect natural
asymptomatic infection in dogs. More importantly, it can also
be used to assess the Leishmania-specific immunity induced
by vaccination (97). The ease of use of this assay makes
it appropriate to veterinary clinical practices for determining
the level of protection induced by the vaccination against
CVL (98). Further, it can be used to analyze vaccination-
induced phenotypic changes in circulating immune cells;
the increased expression of Toll-like receptors, activation
and co-stimulatory molecules, and of inflammation-associated
intracytoplasmic cytokines in neutrophils, monocytes and




CVL is a growing public health concern whose control requires
the use of effective measures to prevent infection and the
development of the disease. Vaccines for CVL represent an
important advance for this control, but the complexity of the
protective response that these vaccines have to induce in the
host makes it difficult their obtaining and the assessment of their
efficacy. The techniques discussed for assessing cell-mediated
immunity in humans and dogs have all demonstrated their
usefulness in this respect and should be used in order to confirm
whether a dog has become protected after vaccination. Tools
for testing specific immunity against CVL are important given
that different vaccines for CVL are on the market and others
are in the pipeline. Comparisons between already registered
vaccines should go beyond confirming negative serological
and parasitological results, but take advantage of cell-mediated
immunity tests. The latter should be used in the different phases
of clinical development of CVL vaccines and be incorporated into
the follow-up of vaccinated animals involved, and into Phase IV
post-marketing trials.
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